---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-072040"
form_type: "8-K"
ticker: null
cik: "0001903464"
company_name: "Aimfinity Investment Corp. I"
filed_at: "2026-06-25T20:05:33+00:00"
generated_at: "2026-06-25T20:08:49.508280+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aimfinity adds two independent director nominees; Docter reports first product shipment and new order

## Summary
- Added William Koschak and Jonathan Bond as independent director nominees for PubCo post-business combination.
- Docter completed first product shipment to Taiwan SECOM subsidiary valued at NT$1.66M; broader project estimated NT$75M.
- Docter received customized mmWave sensor equipment order from Leeway Biomedical for 300 iCARE sleep devices valued at NT$2.268M.
- Potential nationwide expansion of sleep device order to 10,000 units with projected total sales of approximately USD 2.5 million.
- Anticipated hospital projects for smart ward and home-based remote healthcare over next three months, subject to tender.

## SEC filing metadata
- accession: 0001213900-26-072040
- form_type: 8-K
- cik: 0001903464
- company_name: Aimfinity Investment Corp. I
- filed_at: 2026-06-25T20:05:33+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1903464/000121390026072040/0001213900-26-072040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1903464/000121390026072040/ea0295833-8k425_aimfin1.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-072040
- JSON: https://secwatch.observer/filing/0001213900-26-072040.json
- Plain text: https://secwatch.observer/filing/0001213900-26-072040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.